Innovación, terapia y desarrollo farmacéutico en oftalmología
INNOFTAL
![Foto de Innovación, terapia y desarrollo farmacéutico en oftalmología](/img/grupo.png)
![Foto de Hospital General Universitario de Alicante](/img/noimage_org.png)
Hospital General Universitario de Alicante
Alicante, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital General Universitario de Alicante (6)
2024
-
Author Correction: Effectiveness and safety of XEN63 in patients with primary-open-angle glaucoma (Scientific Reports, (2024), 14, 1, (4561), 10.1038/s41598-024-55287-z)
Scientific Reports
-
Effectiveness and safety of XEN63 in patients with primary-open-angle glaucoma
Scientific Reports, Vol. 14, Núm. 1
2022
-
Efficacy, safety and cost-effectiveness of methotrexate, adalimumab or their combination in non-infectious non-anterior uveitis: a protocol for a multicentre, randomised, parallel three arms, active-controlled, phase III open label with blinded outcome assessment study
BMJ open, Vol. 12, Núm. 3, pp. e051378
2021
-
Long-term Follow-up and optimization of infliximab in refractory uveitis due to Behçet Disease: National study of 103 white patients
Journal of Rheumatology, Vol. 48, Núm. 5, pp. 741-750
2019
-
Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases
Arthritis and Rheumatology, Vol. 71, Núm. 12, pp. 2081-2089
2009
-
CYP1B1 mutations in Spanish patients with primary congenital glaucoma: Phenotypic and functional variability
Molecular Vision, Vol. 15, pp. 417-431